Revvity Inc. (NYSE:RVTY) Receives $108.92 Average PT from Analysts

Shares of Revvity Inc. (NYSE:RVTY) have been assigned an average recommendation of “Hold” from the sixteen research firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $108.9167.

RVTY has been the subject of several analyst reports. JPMorgan Chase & Co. dropped their target price on Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. TD Cowen reiterated a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Wall Street Zen cut Revvity from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Zacks Research lowered shares of Revvity from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Finally, Barclays lifted their price target on shares of Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th.

Revvity Stock Up 2.4%

NYSE RVTY opened at $113.21 on Friday. Revvity has a one year low of $81.22 and a one year high of $118.30. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.41 and a current ratio of 1.72. The business has a fifty day moving average price of $104.57 and a 200 day moving average price of $99.53. The company has a market cap of $12.63 billion, a P/E ratio of 54.17, a P/E/G ratio of 2.18 and a beta of 1.09.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. The firm had revenue of $711.12 million for the quarter, compared to the consensus estimate of $704.07 million. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the firm posted $1.01 earnings per share. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. Research analysts anticipate that Revvity will post 5.25 EPS for the current fiscal year.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, August 7th. Shareholders of record on Friday, July 17th will be given a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.2%. Revvity’s payout ratio is presently 13.40%.

Institutional Investors Weigh In On Revvity

A number of institutional investors have recently modified their holdings of the company. Ascentis Independent Advisors acquired a new position in Revvity during the 1st quarter worth about $29,000. CYBER HORNET ETFs LLC acquired a new position in Revvity in the 2nd quarter valued at about $32,000. Cromwell Holdings LLC increased its stake in Revvity by 141.4% during the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after purchasing an additional 198 shares during the period. MUFG Securities EMEA plc purchased a new stake in Revvity during the second quarter worth about $34,000. Finally, SJS Investment Consulting Inc. lifted its position in shares of Revvity by 5,210.0% during the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after purchasing an additional 521 shares in the last quarter. 86.65% of the stock is owned by institutional investors and hedge funds.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.